J.P. Morgan Healthcare Conference 2023 Pharma Partnering

At Roche and Genentech, we are leveraging our unique company structure and culture to build deep and long-lasting collaborations with our partners to translate pioneering science into breakthroughs for patients.

We strongly believe that the key elements to a successful and lasting partnership are trust, shared values and openness. To revolutionize today’s standard of care, we are looking for best or first in class innovation in the following areas:

Roche Pharma Partnering is participating at the J.P. Morgan Healthcare Conference 2023, taking place from January 9-12. We are excited to be back in person and look forward to connecting with you!

We are taking PHC toward a future where treatments are targeted towards individual patient needs and unique profiles.

Partnering opportunities we are looking for:

  • Robust data sets (e.g. to enable biomarker discovery and development, power AI/ML algorithms)

  • Advanced Analytics (artificial intelligence including machine learning and deep-learning models)

  • Digital and mobile technologies (e.g. to optimize treatment administration)

Learn more

Digital and Personalised Healthcare (PHC)

Contact
Michael Scherer
Search & Evaluation Lead Digital & Personalised Healthcare, Pharma Partnering

We are leading the way to advance science in inflammatory and autoimmune diseases.

Partnering opportunities we are looking for:

  • Gastroenterology (IBD), Respiratory (COPD, Asthma, IPF, ILD, SSc), Nephrology (GN, CKD, Transplant, auto-immune skin diseases (Psoriasis, AD), T1D, Celiac disease

    • Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets

Learn more

Immunology

Contact
Jean-Eric Charoin
Search & Evaluation Lead Immunology & Infectious Diseases, Pharma Partnering

We are advancing innovation to combat infectious diseases like HBV, influenza and MDR.

Partnering opportunities we are looking for:

  • Hepatitis B

  • Respiratory Viruses

  • Multidrug-resistant, Gram-negative Bacterial Infections

  • Non-tuberculosis mycoplasma

Learn more

Infectious Diseases

Contact
Jean-Eric Charoin
Search & Evaluation Lead Immunology & Infectious Diseases, Pharma Partnering

We focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders.

Partnering opportunities we are looking for:

  • Neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease)

  • Neuroimmunology and neuroinflammation (e.g. Multiple sclerosis)

  • Neurodevelopment and psychiatry (e.g. Angelman Syndrome, Schizophrenia, and Autism spectrum disorders)

  • Neuromuscular diseases (e.g. SMA and Duchenne Muscular Dystrophy)

Learn more

Neuroscience

Contact
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering

We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy.

Partnering opportunities we are looking for:

  • Oncogenic drivers

  • Synthetic lethality

  • Adaptive and innate immunity

  • Neoantigens

  • Stromal biology

  • Cell therapies

Learn more

Oncology and Cancer Immunotherapy

Contact
Zineb El Fajoui
Search & Evaluation Lead Oncology, Pharma Partnering

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research.

Partnering opportunities we are looking for:

  • Retinal diseases (including AMD, DME, RVO, DR)

  • Glaucoma

  • Dry eye disease

  • Vision restoration through gene therapy and cell-based therapy approaches

Learn more

Ophthalmology

Contact
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering

We are committed to developing new innovations for monogenetic rare diseases.

Partnering opportunities we are looking for:

  • Monogenetic rare diseases

Learn more

Rare Diseases

Contact
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering

We focus on therapeutic modalities and enabling technologies. Partnering opportunities we are looking for:

  • Novel modalities and enabling technologies to expand the druggable target space

  • Targeted or intracellular delivery

  • Artificial intelligence for target and drug discovery

  • Genomic Medicine platforms

Learn more

Research Technologies

Contact
Mark Schiebler
Search & Evaluation Lead Research Technologies, Pharma Partnering

Research & Development is the essence and lifeblood of Roche - and we have a unique way to foster innovation together with our partners in Asia and across the world. Partnering opportunities we are looking for:

  • Innovative biotechs or academic institutions from Asia working on first in class or best in disease opportunities from Discovery to Phase II Development and;

  • Immunology (interferon-driven inflammatory diseases including lupus nephritis and systemic sclerosis, nephrology and renal transplant, with focused MoAs in nucleic acid sensing, interferon production, complement and immune tolerance) and oncology (gastrointestinal cancers, with focused MoAs in novel and/or disease-specific cancer driver genes, synthetic lethality, immunotherapy for enhancing innate immunity and dampening suppression, and cancer extracellular matrix esp. collagen modulation)

Learn more

Pharma partnering in Asia

Contact
Mikio Kasahara
Director Business Development, Japan & Korea, Australia

Alliance & Asset Management

During the collaboration conversations, a dedicated Alliance Manager is assigned as the single point of contact to ensure successful continuation and an enduring relationship with our new partner.

Contact
Urs Schleuniger
Global Head, Alliance & Asset Management

R&D Out-licensing and Commercial Asset Divestment

Out-licensing and divestment decisions enable us to continue our investment in innovative R&D, supporting the development of novel medicines. In addition,it supports the further development of programs that could result in treatments for patients in disease areas and indications that are no longer of strategic focus for Roche and Genentech.

Contact
Jörg Kazenwadel
Head of Asset Management
Contact
Tim Steven
R&D Out-Licensing Director

Related links